UPMC Hillman Cancer Center was among the first in the nation to offer the FDA-approved CAR T-cell therapies listed below and is western Pennsylvania’s most experienced provider, having treated more than 100 patients with CAR T cells.
UPMC also tests new forms of this cutting-edge cancer treatment through clinical trials.
This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.
We're ready to provide you with high-quality, personalized care in one of the nation's most advanced treatment centers.
Your stem cell transplant team will answer all your questions and guide you through the transplant journey
Our cancer researchers work with clinicians to quickly move the most promising research results from their labs into clinical trials. This gives you early access to new and innovative cancer treatments throughout our UPMC Hillman Cancer Center network.